Bardy Diagnostics
Bardy Diagnostics develops the P-wave centric Carnation Ambulatory Monitor (CAM) Patch, a wire-free ECG patch for up to 14-day cardiac monitoring, along with the BDxCONNECT portal and AI-powered AF detection. The company serves electrophysiologists, cardiologists, and hospitals in the United States and operates as a subsidiary of Baxter International Inc.
- Company typePrivate
- Founded2013
- HeadquartersSeattle, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bardy Diagnostics does
Bardy Diagnostics is a US-based developer of ambulatory cardiac monitoring technology, founded in 2013 by electrophysiologist Gust H. Bardy, M.D. The company's flagship product is the Carnation Ambulatory Monitor (CAM) Patch, a single-use, wire-free ECG patch designed for extended wear up to 14 days. The CAM Patch is placed along the sternum to optimize P-wave signal capture, addressing the limited atrial signal clarity that constrains conventional Holter and competing patch monitors. The company complements the device with the BDxCONNECT cloud-based patient management portal (HIPAA-compliant, ISO/IEC 27001 certified, with EHR integration API) and the proprietary CAM Report, a multi-field diagnostic report format that combines near-field, medium-field, and far-field R-R interval views, delivered within an average of under 48 hours after data upload.
The company monetizes through hardware sales of the CAM Patch and professional ECG analysis services performed by CRAT- and CCT-certified technicians (operated via Baxter's Independent Diagnostic Testing Facility), reimbursed under CPT codes for continuous cardiac monitoring of 48 hours to 15 days. An in-house convolutional neural network analyzes ECG recordings and R-R interval data to produce AF yes/no output every half-second, with published performance of 96.82% sensitivity and 99.86% specificity. Bardy sells primarily through a direct enterprise sales force targeting electrophysiologists, cardiologists, hospitals, and health systems, supported by clinical evidence from peer-reviewed head-to-head studies against Holter, Zio XT, and MCT.
Bardy Diagnostics operates from its Bellevue, Washington headquarters with operational centers in Houston TX, New Providence NJ, and Milpitas CA. In 2025, the company was acquired by Baxter International Inc. and now operates as a wholly-owned subsidiary, with all trademarks (BardyDx, CAM, BDx Design) owned by Baxter. The firm is private and does not publicly disclose revenue.
Bardy Diagnostics firmographics
Firmographics- Name
- Bardy Diagnostics
- Legal name
- Bardy Diagnostics, Inc.
- Website
- https://bardydx.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Bardy Diagnostics develops the P-wave centric Carnation Ambulatory Monitor (CAM) Patch, a wire-free ECG patch for up to 14-day cardiac monitoring, along with the BDxCONNECT portal and AI-powered AF detection. The company serves electrophysiologists, cardiologists, and hospitals in the United States and operates as a subsidiary of Baxter International Inc.
- Ownership category
- akta.pro rank
Bardy Diagnostics industry classification
Industry- Product category
- Ambulatory Cardiac Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Laboratories (621511)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)
Keywords
Where Bardy Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Bardy Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Ambulatory Cardiac Monitoring Services: The company generates revenue through the sale of CAM Patch devices and associated monitoring services. Services include ECG data collection, analysis by certified ECG technicians (CRAT- and CCT-certified), and CAM Report generation. Reimbursement is based on CPT codes for continuous cardiac monitoring ranging from 48 hours to 15 days. The company provides billing support through its Customer Experience Team and offers multiple payment options for patients including phone, online, and mail payment methods.
- ECG Analysis and Reporting Services: Revenue generated from professional ECG analysis services provided through Baxter's IDTF (Independent Diagnostic Testing Facility) within the United States. Reports are prepared by certified technicians and provided within 2 business days. Practices can also choose to analyze data using their own in-house ECG technicians.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels8 records
Bardy Diagnostics product offering
Product offeringCore offering
Bardy Diagnostics develops, manufactures, and sells the Carnation Ambulatory Monitor (CAM) Patch, a single-use P-wave centric ECG patch monitor for up to 14 days of continuous ambulatory recording, paired with the BDxCONNECT cloud-based patient management portal and the proprietary multi-field CAM Report. Revenue is generated from CAM Patch device sales and associated ECG analysis and reporting services performed by certified technicians, with reimbursement under CPT codes for continuous cardiac monitoring ranging from 48 hours to 15 days.
Product overview
Bardy Diagnostics offers a unified ambulatory cardiac monitoring solution centered on three integrated components: the Carnation Ambulatory Monitor (CAM) Patch (a P-wave centric ECG patch designed for up to 14-day extended wear), the BDxCONNECT cloud-based patient management and EHR integration portal, and the CAM Report system (delivering multi-view ECG analysis within 2 business days). These products work together as an end-to-end solution enabling patient monitoring, secure data upload, expert ECG analysis by certified technicians, and rapid clinical reporting.
Differentiator
Problem solved
Functional benefit
Brands
- CAM (Carnation Ambulatory Monitor): P-wave centric ECG patch monitor for ambulatory cardiac monitoring, designed to optimize P-wave signal capture and deliver high diagnostic accuracy for detecting arrhythmias.
- BDxCONNECT
- CAM Report
Products and services
- Carnation Ambulatory Monitor (CAM) Patch Lightweight, wire-free, single-use P-wave centric ECG patch monitor designed for up to 14 days of continuous ambulatory recording along the sternum, enabling patients to mark symptoms via a button and capturing every heartbeat with optimized atrial signal clarity for arrhythmia diagnosis.
- BDxCONNECT Portal HIPAA-compliant, ISO/IEC 27001-certified web-based patient management portal that supports patient registration, secure cloud transmission of patch monitor data, EHR integration via API, automatic notifications and alerts, and physician-editable online reporting.
- CAM Report Proprietary report format providing multiple diagnostic field views including Near-Field (8-second traditional view with R-R measurements), Medium-Field (56-second snapshot with 24 seconds pre/post episode), and Far-Field (40-minute R-R interval plot with 20 minutes pre/post) for enhanced arrhythmia diagnosis.
- ECG Analysis and Reporting Services Professional ECG analysis services performed by CRAT- and CCT-certified ECG technicians, with CAM Reports prepared within 2 business days and practices retaining the option to perform analysis using their own in-house ECG technicians.
Quantifiable outcome
- 96% of patients prefer CAM Patch over 3-lead standard Holter monitor
- +4 more outcomes
Companies that use Bardy Diagnostics
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Bardy Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Bardy Diagnostics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Baxter International Inc.coreBardy Diagnostics is now part of Baxter. The company operates as Bardy Diagnostics, Inc., a subsidiary of Baxter International Inc. All trademarks (BardyDx, Bardy Diagnostics, BDx Design, CAM) are owned by Baxter International Inc. or its subsidiaries. The redirect page confirms 'Bardy Diagnostics is now part of Baxter.'
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
Bardy Diagnostics competitors and assessment
Company assessmentDirect peers
- iRhythm Technologies: Public competitor (Zio patch) and the most direct peer — Bardy explicitly benchmarks clinical performance against Zio XT in published head-to-head studies, with overlapping electrophysiologist and cardiologist customer base.
- AliveCor: Maker of KardiaMobile ECG devices and AI-based AF detection algorithms; addresses the same electrophysiologist and cardiologist customer base for arrhythmia detection, though primarily via handheld/smartphone rather than patch form factor.
Emerging players
- SmartCardia: Offers a 7-lead wearable ECG patch with AI-powered arrhythmia detection; competes in ambulatory cardiac monitoring with overlapping remote-monitoring use cases targeting similar cardiology customers.
- HeartBeam: Developer of a credit-card-sized 3D ECG device for remote cardiac monitoring with AI-driven synthesis; competes in ambulatory arrhythmia detection with overlapping cardiology customer base.
- Cardiac Insight: Developer of the Cardea SOLO wearable ECG sensor and AI-based arrhythmia analysis; smaller, earlier-stage competitor in the same ambulatory cardiac patch category with overlapping electrophysiologist customers.
Regional players
- Compumedics: Australia-based developer of diagnostic ECG, Holter, and sleep monitoring systems; comparable in ambulatory cardiac monitoring hardware/services but primarily serves Asia-Pacific and select international markets rather than US focus of Bardy.
Broad incumbents
- GE Healthcare (MUSE Cardiology): Provides ECG management systems, Holter analysis, and cardiac diagnostic infrastructure widely deployed in hospitals; competes indirectly via incumbent ECG analysis platforms that integrate with hospital cardiology workflows.
- Boston Scientific (Preventice Solutions): Acquired Preventice Solutions (BodyGuardian) to enter remote cardiac monitoring; broader medtech incumbent now offering ambulatory ECG patch monitoring services directly competing with CAM Patch for cardiology accounts.
- Philips (BioTelemetry/Cardiac Monitoring): Acquired BioTelemetry to offer a broad portfolio including MCT (mobile cardiac telemetry) and ECG monitoring services; competes in ambulatory cardiac monitoring space though as part of a much larger diagnostic and patient monitoring portfolio.
- Hillrom / Baxter Patient Monitoring: Hillrom (now part of Baxter, parent of Bardy Diagnostics) provides Welch Allyn vital signs and bedside patient monitoring; potential channel partner and broader incumbent in hospital-based cardiac and patient monitoring.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Bardy Diagnostics social profiles
Digital presenceBardy Diagnostics compliance and trust
Trust signalCompliance2 records
Bardy Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bardy Diagnostics leadership team
Management profileNumber of profiles
Profiles5 records
Bardy Diagnostics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bardy Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bardy Diagnostics
What does Bardy Diagnostics do?
Bardy Diagnostics develops, manufactures, and sells the Carnation Ambulatory Monitor (CAM) Patch, a single-use P-wave centric ECG patch monitor for up to 14 days of continuous ambulatory recording, paired with the BDxCONNECT cloud-based patient management portal and the proprietary multi-field CAM Report. Revenue is generated from CAM Patch device sales and associated ECG analysis and reporting services performed by certified technicians, with reimbursement under CPT codes for continuous cardiac monitoring ranging from 48 hours to 15 days.
Is Bardy Diagnostics a public or private company?
Bardy Diagnostics is a private company. It is classified as corporate owned and is currently operating.
When was Bardy Diagnostics founded?
Bardy Diagnostics was founded in 2013. It employs 11 to 50 people.
Where is Bardy Diagnostics based?
Bardy Diagnostics is headquartered in Seattle, United States, in the North America region.
How does Bardy Diagnostics make money?
Two revenue lines are on record. Ambulatory Cardiac Monitoring Services are the primary driver. The others are ECG Analysis and Reporting Services.
Who are Bardy Diagnostics's main competitors?
Direct peers on record are iRhythm Technologies and AliveCor. Emerging players are SmartCardia, HeartBeam and Cardiac Insight. Compumedics is listed as a regional player. Broad incumbents are GE Healthcare (MUSE Cardiology), Boston Scientific (Preventice Solutions), Philips (BioTelemetry/Cardiac Monitoring) and Hillrom / Baxter Patient Monitoring.
Does Bardy Diagnostics have an API?
No public API is recorded for Bardy Diagnostics.
What industry is Bardy Diagnostics in?
Bardy Diagnostics's product category is Ambulatory Cardiac Monitoring Devices. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders). Its NAICS code is 334510 and its SIC code is 3845.